Hudson Bay Capital Management
IONS icon

Hudson Bay Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Hudson Bay Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.5M Sell
145,000
-150,100
-51% -$11.3M 0.03% 332
2026
Q1 		$22.2M Sell
295,100
-179,900
-38% -$14.2M 0.08% 176
2025
Q4 		$37.6M Sell
475,000
-40,000
-8% -$3.01M 0.12% 152
2025
Q3 		$33.7M Sell
515,000
-235,000
-31% -$11.5M 0.11% 154
2025
Q2 		$29.6M Sell
750,000
-299,900
-29% -$9.81M 0.1% 158
2025
Q1 		$31.7M Buy
1,049,900
+228,700
+28% +$7.49M 0.1% 188
2024
Q4 		$28.7M Buy
821,200
+54,300
+7% +$2.03M 0.1% 195
2024
Q3 		$30.7M Buy
766,900
+400,900
+110% +$18.7M 0.12% 125
2024
Q2 		$17.4M Buy
366,000
+30,500
+9% +$1.25M 0.08% 151
2024
Q1 		$14.5M Buy
335,500
+190,500
+131% +$9.08M 0.08% 134
2023
Q4 		$7.34M Sell
145,000
-45,000
-24% -$2.16M 0.05% 239
2023
Q3 		$8.62M Sell
190,000
-85,000
-31% -$3.51M 0.07% 183
2023
Q2 		$11.3M Sell
275,000
-30,800
-10% -$1.18M 0.08% 156
2023
Q1 		$10.9M Buy
305,800
+80,800
+36% +$3.03M 0.09% 155
2022
Q4 		$8.5M Buy
225,000
+25,200
+13% +$1.06M 0.09% 213
2022
Q3 		$8.84M Buy
199,800
+14,800
+8% +$624K 0.08% 208
2022
Q2 		$6.85M Sell
185,000
-25,000
-12% -$943K 0.05% 302
2022
Q1 		$7.78M Sell
210,000
-95,000
-31% -$3.11M 0.11% 209
2021
Q4 		$9.28M Buy
305,000
+40,000
+15% +$1.26M 0.09% 157
2021
Q3 		$8.89M Buy
265,000
+80,000
+43% +$3.01M 0.12% 163
2021
Q2 		$7.38M Buy
185,000
+54,600
+42% +$2.14M 0.09% 212
2021
Q1 		$5.86M Sell
130,400
-29,600
-19% -$1.65M 0.07% 241
2020
Q4 		$9.05M Buy
160,000
+35,000
+28% +$1.74M 0.1% 127
2020
Q3 		$5.93M Sell
125,000
-15,000
-11% -$833K 0.09% 204
2020
Q2 		$8.25M Buy
140,000
+95,000
+211% +$5.28M 0.14% 124
2020
Q1 		$2.13M Buy
45,000
+15,000
+50% +$836K 0.05% 258
2019
Q4 		$1.81M Buy
+30,000
New +$1.79M 0.04% 293
2018
Q4 		– Sell
-40,000
Closed -$2.06M – 839
2018
Q3 		$2.06M Sell
40,000
-70,000
-64% -$3.29M 0.03% 462
2018
Q2 		$4.58M Buy
110,000
+50,000
+83% +$2.22M 0.06% 309
2018
Q1 		$2.65M Buy
+60,000
New +$3.05M 0.05% 390

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Hudson Bay Capital Management's IONS Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Ionis Pharmaceuticals (IONS) stake by 51% in Q2 2026, selling an estimated $11.3M and leaving 145,000 shares worth $11.5M. The position accounts for 0.03% of the portfolio, ranked #332.

Hudson Bay Capital Management first reported a position in IONS in Q1 2018 and has held it in 30 quarters since. The position peaked at $37.6M in Q4 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Hudson Bay Capital Management held 145,000 shares of Ionis Pharmaceuticals worth $11.5M as of Q2 2026.
  • Hudson Bay Capital Management sold 150,100 Ionis Pharmaceuticals shares in Q2 2026, an estimated $11.3M.
  • Ionis Pharmaceuticals made up 0.03% of Hudson Bay Capital Management's portfolio in Q2 2026, its #332 holding.
  • Hudson Bay Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2018 and has held it in 30 quarters since.
  • Hudson Bay Capital Management's Ionis Pharmaceuticals position peaked at $37.6M in Q4 2025.
  • 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.